Anne-Sophie de Faucigny
Public Communications Contact bei GETLINK SE
Aktive Positionen von Anne-Sophie de Faucigny
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
GETLINK SE | Public Communications Contact | 01.10.2022 | - |
Karriereverlauf von Anne-Sophie de Faucigny
Ehemalige bekannte Positionen von Anne-Sophie de Faucigny
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Yposkesi
Yposkesi BiotechnologyHealth Technology Part of SK, Inc., Yposkesi is a French-based CDMO that offers bioprocess development and CGMP manufacturing services for AAV and lentiviral vector production. The company is based in Corbeil-Essonnes, France. The French company provides support for gene therapy and aims to provide the best and most complete viral vector solutions. Yposkesi provides flexibility to develop the best process for cell and gene therapy production and process for viral vector. The company was founded in 2015, and Alain Lamproye has been the CEO of the company since 2017. Yposkesi was acquired by SK Pharmteco, Inc. on March 31, 2021. | Direktor/Vorstandsmitglied | 01.01.2018 | 01.01.2021 |
Ausbildung von Anne-Sophie de Faucigny
Institut d’Études Politiques de Toulouse | Graduate Degree |
Statistik
International
Frankreich | 4 |
Operativ
Director/Board Member | 1 |
Public Communications Contact | 1 |
Graduate Degree | 1 |
Sektoral
Health Technology | 2 |
Transportation | 2 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
GETLINK SE | Transportation |
Private Unternehmen | 1 |
---|---|
Yposkesi
Yposkesi BiotechnologyHealth Technology Part of SK, Inc., Yposkesi is a French-based CDMO that offers bioprocess development and CGMP manufacturing services for AAV and lentiviral vector production. The company is based in Corbeil-Essonnes, France. The French company provides support for gene therapy and aims to provide the best and most complete viral vector solutions. Yposkesi provides flexibility to develop the best process for cell and gene therapy production and process for viral vector. The company was founded in 2015, and Alain Lamproye has been the CEO of the company since 2017. Yposkesi was acquired by SK Pharmteco, Inc. on March 31, 2021. | Health Technology |
- Börse
- Insiders
- Anne-Sophie de Faucigny
- Erfahrung